Carregant...
Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer
HER2 is an important predictive marker for response to trastuzumab and lapatinib in breast cancer. It is also a powerful prognostic marker in node-positive patients. Although standardized assays are used to help select patients for anti-HER2 therapy, there are no standardized criteria for assessing...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2009
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3063383/ https://ncbi.nlm.nih.gov/pubmed/19252432 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PAS.0b013e31819437f9 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|